Clascoterone for hair loss: the first new treatment in 30 years just showed stunning trial results

No new drugs. No fresh approaches. Just the same two treatments we’ve had since the 1990s.

That changed in December 2025.

Cosmo Pharmaceuticals announced the results of its Phase III clinical trials on clascoterone, and the numbers are turning heads. 539% improvement in hair regrowth compared to placebo. Zero reported cases of sexual side effects across nearly 1,500 trial participants.

For the millions of men dealing with androgenetic alopecia (male pattern baldness), this is genuinely big news. But what’s actually behind that eye-catching percentage? Does clascoterone genuinely regrow hair, or does it simply put the brakes on loss? How does it stack up against minoxidil and finasteride?

And perhaps most importantly: could it ever replace hair transplantation?

Why clascoterone is different from everything we’ve had before

To appreciate why this matters, it helps to understand how baldness actually works.

In men with a genetic predisposition, a hormone called dihydrotestosterone (DHT) latches onto receptors in the hair follicles. Over time, this causes hairs to thin, shrink, and eventually vanish altogether. Dermatologists call this follicular miniaturisation.

Until now, we’ve had three main strategies to tackle it:

• Minoxidil doesn’t go anywhere near DHT. It’s a vasodilator that boosts blood flow to the scalp and directly encourages hair growth. It works well for plenty of people, but it doesn’t address the hormonal root cause. Stop using it, and the hair falls out again.
• Finasteride tackles the problem at its source, but systemically. It blocks the enzyme (5-alpha reductase) responsible for converting testosterone into DHT, cutting DHT production by around 70% throughout the body. Effective, yes, but this whole-body approach explains those much-discussed side effects. A meta-analysis in Acta Dermato-Venereologica found the risk of sexual dysfunction rises by 57% compared to placebo.
• Clascoterone takes an entirely different route, which is what makes it so exciting.

Rather than reducing DHT production, it stops DHT from binding to hair follicles in the first place. Its molecular structure mimics DHT so closely that it ‘occupies’ the receptors before DHT can get there. DHT continues circulating in your bloodstream, but it can’t damage your hair.

Because clascoterone barely enters the systemic circulation, it shouldn’t interfere with hormones elsewhere in your body. That’s the real breakthrough here: anti-androgen effectiveness without the systemic baggage.

539% regrowth: impressive, but what does it actually mean?

Cosmo Pharmaceuticals ran two identical trials involving nearly 1,500 men with baldness. Over six months, half applied a 5% clascoterone solution twice daily whilst the other half used a placebo.

The results showed a 539% relative improvement in one trial and 168% in the other.

The gap between those numbers might seem odd given identical protocols, but the company explains that the actual number of hairs regrown was similar in both cases. The difference came down to how the placebo groups responded.

A word of caution on interpretation, though. ‘539% better than placebo’ doesn’t mean your hair density will multiply fivefold. The placebo group also showed modest improvement, likely from the daily routine of applying something and massaging the scalp. Clascoterone performed considerably better, but we’re talking about gradual progress. Not an overnight transformation.

The real selling point: a reassuring safety profile

This might be where clascoterone really shines.

Across the 1,500 trial participants, there were no reported cases of erectile dysfunction or reduced libido. None. The side effects that did occur, some redness, mild itching, generally weren’t linked to the drug itself and remained comparable to the placebo group.

For men who’ve been reluctant to try finasteride because of worries about sexual side effects, this matters enormously. Clascoterone works locally on the scalp without disrupting your overall hormonal balance.

Can it replace hair transplantation?

Let’s be straight about this. No. And understanding why is important.

Like every drug treatment for alopecia, clascoterone won’t bring permanently dead follicles back to life. On an area that’s been completely bald for years, no medication will make hair grow. Full stop.

Follicular miniaturisation happens gradually. Hairs thin first, then become wispy vellus hairs, then disappear entirely. Once a follicle is gone, it’s gone.

What clascoterone might do:

• Slow the miniaturisation of follicles that are still active
• Thicken hair that’s already thinning
• Help maintain your current density for longer

What it won’t do:

• Regrow hair where you’ve been bald for years
• Restore a receding hairline
• Fill in areas where follicles have died off

For those situations, a hair transplant in Turkey remains the only option that can genuinely restore density where there isn’t any.

That said, clascoterone could prove excellent as a post-transplant treatment. Protecting your remaining native hair without finasteride’s side effects? That’s genuinely useful.

When can we expect it?

Cosmo Pharmaceuticals plans to wrap up a twelve-month safety study by spring 2026, after which they’ll submit approval applications to the US FDA and the European Medicines Agency. If everything proceeds smoothly, we could see it on the market by 2027.

Until then, current options remain perfectly valid. Minoxidil stimulates growth. Finasteride, despite its reputation, is effective and well-tolerated by most patients. And for established baldness, transplantation is still the only real solution.

Key takeaways

Clascoterone represents a genuine step forward. A new mechanism of action after three decades of status quo, an encouraging safety profile, and promising results for hair thickness.

But it’s not a miracle. It won’t conjure hair on a bald scalp, and you’ll need to wait another couple of years before trying it.

The bottom line? Worth watching. Worth getting excited about, even. But not worth putting off treatment you could start today.

Rosette, C., et al. (2019). Cortexolone 17α-Propionate (Clascoterone) is an Androgen Receptor Antagonist in Dermal Papilla Cells In Vitro. Journal of Drugs in Dermatology, 18(2), 197-201. https://pubmed.ncbi.nlm.nih.gov/30811143/

Liu, L., et al. (2019). Adverse Sexual Effects of Treatment with Finasteride or Dutasteride for Male Androgenetic Alopecia. Acta Dermato-Venereologica, 99(1), 12-17. https://pubmed.ncbi.nlm.nih.gov/30206635/

Devjani, S., et al. (2023). Androgenetic Alopecia: Therapy Update. Drugs, 83(8), 701-715. https://pmc.ncbi.nlm.nih.gov/articles/PMC10173235/

Dhillon, S. (2020). Clascoterone: First Approval. Drugs, 80, 1745-1750. https://pubmed.ncbi.nlm.nih.gov/33030710/

ClinicalTrials.gov. NCT05910450 (SCALP 1) et NCT05914805 (SCALP 2). https://clinicaltrials.gov/

Cosmo Pharmaceuticals. (3 December 2025). Positive Top-Line Phase 3 Results for Clascoterone Solution in Androgenetic Alopecia [Press release].